Harrow, Inc. Stock price

Equities

HROW

US4158581094

Pharmaceuticals

Real-time Estimate Cboe BZX 11:40:01 2024-03-28 am EDT 5-day change 1st Jan Change
12.74 USD +0.12% Intraday chart for Harrow, Inc. +21.17% +14.46%
Sales 2024 * 186M Sales 2025 * 261M Capitalization 450M
Net income 2024 * -11M Net income 2025 * 28M EV / Sales 2024 * 2.42 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.72 x
P/E ratio 2024 *
-40.6 x
P/E ratio 2025 *
17.8 x
Employees 315
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.41%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.19%
1 week+21.01%
Current month+17.60%
1 month+8.80%
3 months+16.26%
6 months-11.41%
Current year+13.66%
More quotes
1 week
10.42
Extreme 10.42
12.87
1 month
9.30
Extreme 9.3
12.87
Current year
9.13
Extreme 9.13
12.87
1 year
7.60
Extreme 7.6
28.25
3 years
5.40
Extreme 5.4
28.25
5 years
3.33
Extreme 3.33
28.25
10 years
1.35
Extreme 1.35
28.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 05-12-31
Director of Finance/CFO 41 11-11-30
Investor Relations Contact - -
Members of the board TitleAgeSince
Chief Executive Officer 51 05-12-31
Director/Board Member 65 Jan. 25
Director/Board Member 69 Jan. 25
More insiders
Date Price Change Volume
24-03-28 12.82 +0.71% 72 521
24-03-27 12.73 +1.19% 530,646
24-03-26 12.58 +4.83% 738,221
24-03-25 12 +4.35% 1,046,711
24-03-22 11.5 +8.70% 1,285,640

Delayed Quote OTC Markets, March 27, 2024 at 04:00 pm EDT

More quotes
Harrow, Inc., formerly Harrow Health, Inc., is a eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides comprehensive portfolio of prescription and non-prescription pharmaceutical products. The Company offers pharmaceutical products for ophthalmic surgeries in the United States, as well as medications prescribed to treat patients managing chronic and acute eye conditions, such as dry eye disease, glaucoma, allergies, infections, and other ophthalmic inflammatory conditions. It serves over 10,000 doctors, hospitals, and ambulatory service centers (ASCs) and regularly ship to over 1,500 institutional accounts each month.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.73 USD
Average target price
27.53 USD
Spread / Average Target
+116.29%
Consensus
  1. Stock
  2. Equities
  3. Stock Harrow, Inc. - OTC Markets